An excellent meeting.
Marc FluittVP National Accounts
PAM LAB
Create best practice Pricing and Reimbursement Strategies
- Understand the key elements and pricing agreements
- Hear the latest updates from the new PMPRB Director
- Establish a proven formula for reimbursement success
Ensure Government Approval and Develop Relationships
- Develop best practice in this highly complex but opportunistic environment
- Understand the strategies needed create national coverage for your drug
- Network with the most senior level and influential representatives in the industry.
Add Value for Stakeholders to Achieve Effective Drug Approval in the Canadian Market.
The governmental and provincial processes in Canada pose pharma difficult early challenges to gaining entry into this important market. The overriding issue is the need for productive Market Access strategies that align with company needs, for more effective drug approval.
How?
- Create faultless internal Market Access management
- Understand the key ingredients for pricing & reimbursement strategies
- Effective CDR engagement
- Improve your federal & provincial government communication
This is your passport to learn, discuss and network with some of the key players in the Canadian Market Access environment. Take the first step to ensure you're not left behind by your competitors and check out the brochure now to see the full agenda and speaker line up for this exclusive summit.
Still not sure if this summit is for you?
94% of the 09 delegates plan to attend the 2010 Market Access summit in October. With outstanding pretentions from the CDR, PMPRB, CCO, Rx&D as well as industry best practice examples from Bayer, Roche, Johnson & Johnson (J&J), Bristol Myers Squibb (BMS), Takeda and AstraZeneca (AZ) it's clear to understand why.
If you missed the 09 Market Access summit. Catch up on presentations by Doug Grant, VP, Corporate Affairs, Bayer, Krista Scaldwell, VP Market Access, BMS, Brian O'Rouke, VP, CDR and Barbara Ouellet, Executive Director, PMPRB here: 09 Presentations.
Speakers Confirmed Include
Wendy Zatylny
Vice President, Government Affairs,
Rx&D
David Shum
Director Reimbursement Health Economics,
Roche
Doug Grant
Vice President Corporate Affairs,
Bayer
Geroge Wyatt
Managing Director,
Wyatt Health
Philip Schwab
VP Industry Rekations,
BIOTECanada
Bill Dempster
Director,
Global Public Affairs
Jeffery Graham
Partner,
Borden Ladner Gervais LLP
Adam Siskind
Associate Principal Practice Lead, Canadian Market Access,
ZS Associates
Lesia Babiak
Executive Director, Government Affairs, LifeScan & Director, J&J Corporate,Government Affairs
Norma Beauchamp
Vice President Policy and Reimbursement
Novartis
Claudia Neuber
Director of Pricing and Contracting,
AstraZeneca
Olaf Koester
Director, Drug Management Policy Unit, Corporate and Provincial Program Support
Manitoba Health
